Peptide InjectionsAI
Moderate evidence

Ara-290

Peptide therapy: benefits, side effects, cost and protocols

C51H84N16O21

1,257.3 g/mol / CID 91810664
C51H84N16O21

ARA-290 (cibinetide) is an 11-amino acid peptide derived from erythropoietin (EPO) that targets the innate repair receptor without hematopoietic side effects. It has been studied for neuropathy, tissue repair, and chronic inflammatory conditions in multiple human clinical trials.

ByChris Riley(CFA)|Updated

Sources: FDA / PubMed / ClinicalTrials.gov View

FDA status
Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.
Evidence
Moderate Evidence

Who Ara-290 is usually considered for

  • Neuropathic pain research
  • Tissue repair
  • Nerve protection
  • Limited human trials or strong preclinical

How Ara-290 works

Selectively activates the innate repair receptor (IRR) for tissue-protective effects without erythropoietic activity.

Key studies

65 papers on PubMed / 32 human trials

  1. 01

    Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study

  2. 02

    Heij L, Niesters M, Swartjes M et al

    Mol Med / Mol Med / Phase 2

    ARA 290 safely reduced small fiber neuropathy symptoms and improved pain and physical functioning versus placebo.

  3. 03

    ARA 290 safely reduced small fiber neuropathy symptoms and improved pain and physical functioning versus placebo

  4. 04

    ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes

  5. 05

    Brines M, Dunne AN, van Velzen M et al

    Mol Med / Mol Med / Phase 2

    28 days treatment plus 28 days follow-up

  6. 06

    ARA 290 improved hemoglobin A1c, lipid profiles, neuropathic symptoms, and corneal nerve fiber density in type 2 diabetes

  7. 07

    ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density

  8. 08

    Dahan A, Dunne A, Swartjes M et al

    Mol Med / Mol Med / RCT

  9. 09

    ARA 290 significantly improved neuropathic symptoms and increased corneal nerve fiber density in sarcoidosis patients

  10. 10

    Managing fatigue in sarcoidosis - A systematic review of the evidence

    Chron Respir Dis / Chron Respir Dis

Ara-290 compound data

C51H84N16O21
1257.3 g/mol
91810664 ↗
(4S)-5-[[(1S)-4-amino-1-[[(1S)-1-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-3-amino-1-[[(1S)-2-[[(1S)-1-carboxy-2-hydroxy-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]-3-oxo-propyl]carbamoyl]-3-methyl-butyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-3-carboxy-propyl]carbamoyl]-3-methyl-butyl]carbamoyl]-4-oxo-butyl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid

Ara-290 questions

What is ARA-290?

ARA-290 is a peptide derived from erythropoietin (EPO) researched for tissue repair and neuropathic pain applications without the blood-stimulating effects of EPO.

How does ARA-290 work?

Selectively activates the innate repair receptor (IRR) for tissue-protective effects without erythropoietic activity.

Is ARA-290 legal to buy?

ARA-290 is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.

Where can I buy ARA-290?

ARA-290 is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.

What category does ARA-290 belong to?

ARA-290 is primarily classified as a tissue repair & healing peptide. Peptides studied for their potential in wound healing, tendon/ligament repair, gut healing, and general tissue regeneration.

What are the research benefits of ARA-290?

ARA-290 has been studied for: Neuropathic pain research, Tissue repair, Nerve protection. Neuropathic pain/repair research peptide.

Ara-290 in the news

News aggregated via Google News. Inclusion does not imply endorsement.

Considering Ara-290?

The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.

Take the quiz